Intensificar o reforço das abordagens de monitorização do tratamento através dos testes da carga viral, assim como o diagnóstico pediátrico precoce, será fundamental para garantir cuidados e tratamentos de boa qualidade e o êxito dos programas. Considerar uma boa rede de diagnósticos, tipos... de amostras, intervenções e estratégias em cada um dos países e em todas as partes interessadas nacionais, regionais e parceiros contribuirá para apoiar este esforço, melhorar a colaboração e maximizar o investimento nos diagnósticos para um impacto clínico visível.
more
L’expansion de la mise en œuvre des approches de suivi du traitement par la réalisation de tests de mesure de la charge virale et de tests de diagnostic chez le nourrisson sera indispensable pour garantir la qualité des soins et des traitements ainsi que le succès des programmes. Le fait de ch...oisir le réseau de diagnostic, les types d’échantillons ainsi que les interventions et les stratégies les plus appropriés dans chaque pays et pour chaque partenaire au niveau national et régional permettra de soutenir cet effort, de renforcer la collaboration et d’optimiser les investissements réalisés dans la mise en œuvre des tests en vue d’obtenir des effets manifestes.
more
This document describes the key areas that national governments should consider for the introduction and scale-up of point-of-care (POC) diagnostics within national programmes, as new innovative POC technologies are being introduced into the market. The next steps taken to include these new innovati...ons within the broader context of national diagnostic networks of conventional laboratories could influence the achievement of the 2030 Fast Track targets for ending the AIDS epidemic.
POC diagnostics, when strategically introduced and integrated into national diagnostic networks, may help catalyse changes that improve the way diagnostics and clinical services are delivered. This document distils this understanding based on programmatic and market experiences of introducing POC diagnostics through catalytic investments in POC HIV technologies across numerous countries in sub-Saharan Africa.
more
EClinicalMedicine 1 (2018) 21–27
https://doi.org/10.1016/j.eclinm.2018.06.005
2589-5370/© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
EClinicalMedicine: journal homepage: https://www.jo...urnals.elsevier.com/ eclinicalmedicine
Research Paper
more
HIV drug resistance , Users Manual
December 2017
Guidelines
June 2017
HIV strategic information for impact
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.11
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.14
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.12
HIV patient monitoring and case surveillance
PQDx 0179-012-00 WHO
PQDx Public Report
June/2017, version 4.0
PQDx 0027-012-00 WHO
PQDx Public Report
May/2017, version 4.0
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
PQDx 0159-055-00
WHO PQ Public Report
February/2017, version 5.0
PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0
3rd Edition – July 2017
www.msfaccess.org